What was the primary reason for the decrease in net income and diluted EPS?

The decrease in net income and diluted EPS was primarily driven by a decline in gross profit, particularly in the Pharmaceutical Distribution segment, due to reduced profits from pharmaceutical price increases and inventory appreciation. This was partially offset by a gain from antitrust litigation settlements and improved cash flow from operations.

How did the company improve its cash flow from operations?

The company improved its cash flow from operations through better inventory management, leading to reduced inventory levels, and a decrease in accounts receivable. These factors, combined with strong operating performance, contributed to the significant increase in cash provided by operating activities.

What is the status of the company's share repurchase program?

The company's board of directors authorized a $500 million share repurchase program. During the quarter, the company repurchased $253 million worth of its common stock, bringing the total repurchased under this program to $397.7 million as of December 31, 2004. The company expects to complete this program in fiscal year 2005.

What are the key challenges or transitions the company is facing?

The company is navigating significant changes in the pharmaceutical supply chain, including the transition from a model dependent on pharmaceutical price increases and inventory appreciation to a fee-for-service model. Additionally, changes stemming from the Medicare Modernization Act, particularly regarding Medicare Part D, could impact the PharMerica segment.

COR 10-Q Quarterly Report Q1 FY2005 — Revenue, Net Income, EPS

Summary

Cencora, Inc. (COR), formerly AmerisourceBergen Corporation, reported its financial results for the quarterly period ending December 31, 2004. The company experienced a slight decrease in operating revenue to $12.2 billion, primarily driven by declines in both its Pharmaceutical Distribution and PharMerica segments. Despite the revenue dip, the company saw a significant boost in cash flow from operations, which more than doubled compared to the previous year's quarter, reaching $122.7 million. This was supported by improved inventory management and a reduction in accounts receivable. Key to the quarter's financial performance was a $18.8 million gain recognized from antitrust litigation settlements, which partially offset increased operating expenses related to facility consolidations and severance costs. The company also successfully managed its debt, repaying $180 million of its term loan facility and continuing its share repurchase program, buying back $253 million worth of its common stock. While net income saw a decline of 41% year-over-year to $64.4 million, diluted EPS also decreased to $0.60 from $0.94, reflecting a more challenging operating environment. The company continues to navigate changes in the pharmaceutical supply chain, including the transition to a fee-for-service model.

Key Highlights

1Operating revenue for the quarter ended December 31, 2004, was $12.2 billion, a slight decrease from the prior year.
2Net income decreased by 41% to $64.4 million, with diluted earnings per share at $0.60.
3Cash provided by operating activities significantly increased to $122.7 million, up from $454.4 million used in the prior year's quarter.
4The company recognized an $18.8 million gain from antitrust litigation settlements.
5Facility consolidations and employee severance costs amounted to $5.1 million during the quarter.
6The company repaid $180 million of its term loan facility and repurchased $253 million of its common stock.
7Inventory turnover improved to 8.8 times, and average days sales outstanding for the Pharmaceutical Distribution segment decreased.

Cencora, Inc. Quarterly Report for Q1 Ended Dec 31, 2004

Summary

Key Highlights

Frequently Asked Questions